NO20054876L - Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds - Google Patents

Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds

Info

Publication number
NO20054876L
NO20054876L NO20054876A NO20054876A NO20054876L NO 20054876 L NO20054876 L NO 20054876L NO 20054876 A NO20054876 A NO 20054876A NO 20054876 A NO20054876 A NO 20054876A NO 20054876 L NO20054876 L NO 20054876L
Authority
NO
Norway
Prior art keywords
drug
compounds
phenyltetrahydroisoquinolines
substituted
preparation
Prior art date
Application number
NO20054876A
Other languages
Norwegian (no)
Other versions
NO20054876D0 (en
Inventor
Klaus Wirth
Hans-Jochen Lang
Wendelin Frick
Armin Hofmeister
Markus Bleich
Uwe Heinelt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054876D0 publication Critical patent/NO20054876D0/en
Publication of NO20054876L publication Critical patent/NO20054876L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det beskrives forbindelser med formel I der RI til R9 har de angitte betydninger. Medikamenter inneholdende denne type forbindelse, kan benyttes ved prevensjon eller terapi av forskjellige sykdommer. Forbindelsene kan blant annet benyttes for renale sykdommer som akutt eller kronisk nyresvikt, for forstyrrelser i biliarfunksjonene eller mot respiratoriske forstyrrelser, som snorking eller søvnapne, eller mot apopleksi.Compounds of formula I are described in which R 1 to R 9 have the meanings specified. Medications containing this type of compound can be used in the prevention or therapy of various diseases. The compounds can be used, among other things, for renal diseases such as acute or chronic renal failure, for biliary disorders or for respiratory disorders, such as snoring or sleep apnea, or for apoplexy.

NO20054876A 2003-03-24 2005-10-21 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds NO20054876L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312963A DE10312963A1 (en) 2003-03-24 2003-03-24 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
PCT/EP2004/002497 WO2004085404A1 (en) 2003-03-24 2004-03-11 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds

Publications (2)

Publication Number Publication Date
NO20054876D0 NO20054876D0 (en) 2005-10-21
NO20054876L true NO20054876L (en) 2005-12-06

Family

ID=32946086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054876A NO20054876L (en) 2003-03-24 2005-10-21 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds

Country Status (23)

Country Link
EP (1) EP1613600B1 (en)
JP (1) JP2006521306A (en)
KR (1) KR20050115304A (en)
CN (1) CN100364978C (en)
AR (1) AR043741A1 (en)
AU (1) AU2004224242B2 (en)
BR (1) BRPI0408744A (en)
CA (1) CA2519658A1 (en)
DE (1) DE10312963A1 (en)
HK (1) HK1090042A1 (en)
HR (1) HRP20050843A2 (en)
MA (1) MA27751A1 (en)
ME (1) MEP42908A (en)
MX (1) MXPA05010003A (en)
MY (1) MY139498A (en)
NO (1) NO20054876L (en)
NZ (1) NZ542608A (en)
PE (1) PE20050311A1 (en)
RS (1) RS20050713A (en)
RU (1) RU2343147C2 (en)
TW (1) TW200510321A (en)
WO (1) WO2004085404A1 (en)
ZA (1) ZA200506422B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046492A1 (en) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005001411A1 (en) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005033100B3 (en) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation
DE102005044817A1 (en) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102006012544A1 (en) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituted 1-amino-4-phenyl-dihydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
CA2654915C (en) * 2006-06-29 2015-07-28 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
RU2010151605A (en) * 2008-05-19 2012-06-27 Актелион Фармасьютиклз Лтд (Ch) NEW TETRAHYDROISOCHINOLINS AS ANTI-MALARIAN AGENTS
WO2010078449A2 (en) * 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2748147B1 (en) 2011-08-25 2017-08-02 St. Jude Children's Research Hospital Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
HUE044550T2 (en) 2013-04-12 2019-11-28 Ardelyx Inc Nhe3-binding compounds and methods for inhibiting phosphate transport
RU2538085C2 (en) * 2013-05-08 2015-01-10 Любовь Демьяновна Шаманская Agent for control of exo-parasites of animals
CN106536502B (en) * 2014-07-25 2019-03-05 大正制药株式会社 The phenyl tetrahydro isoquinoline compound being substituted by heteroaryl
CN110267944B (en) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 Compounds useful for the treatment of gastrointestinal disorders
JP2020505333A (en) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Inhibitors of NHE-mediated antiport
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR102681183B1 (en) * 2019-05-16 2024-07-04 일라이 릴리 앤드 캄파니 Sodium-hydrogen exchanger 3 inhibitor compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
JPH06256311A (en) * 1993-02-26 1994-09-13 Nippon Shinyaku Co Ltd Isoquinolinol derivative and medicine
DE19951702A1 (en) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Use of 2-amino-3,4-dihydroquinazolines for the manufacture of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions
ES2304984T3 (en) * 1999-11-03 2008-11-01 Amr Technology, Inc. TETRA-HYDROISOQUINOLINAS OF ARILICA AND HETEROARILICA SUBSTITUTION AND ITS USE TO BLOCK THE RECOVERY OF NOREPINEFRINE, DOPAMINE AND SEROTONINE.
AU784280B2 (en) * 1999-11-03 2006-03-02 Albany Molecular Research, Inc. 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
PL369313A1 (en) * 2001-12-05 2005-04-18 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
DE10161767A1 (en) * 2001-12-15 2003-06-26 Merck Patent Gmbh New 2-guanidino-4-heterocyclyl-quinazoline derivatives, useful as sodium-proton antiporter subtype III inhibitors for treating e.g. respiratory, renal, ischemic or lipid metabolism disorders
DE10163914A1 (en) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as medicament, and medicament containing them
DE10163992A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-aryl-quinazolines

Also Published As

Publication number Publication date
MEP42908A (en) 2011-02-10
JP2006521306A (en) 2006-09-21
DE10312963A1 (en) 2004-10-07
WO2004085404A1 (en) 2004-10-07
MXPA05010003A (en) 2005-11-17
RU2006127170A (en) 2008-02-10
CA2519658A1 (en) 2004-10-07
MY139498A (en) 2009-10-30
NZ542608A (en) 2009-07-31
CN1798737A (en) 2006-07-05
KR20050115304A (en) 2005-12-07
EP1613600A1 (en) 2006-01-11
NO20054876D0 (en) 2005-10-21
TW200510321A (en) 2005-03-16
AR043741A1 (en) 2005-08-10
MA27751A1 (en) 2006-02-01
HRP20050843A2 (en) 2006-09-30
CN100364978C (en) 2008-01-30
RU2343147C2 (en) 2009-01-10
HK1090042A1 (en) 2006-12-15
ZA200506422B (en) 2007-02-28
AU2004224242B2 (en) 2010-03-18
RS20050713A (en) 2007-11-15
BRPI0408744A (en) 2006-04-18
EP1613600B1 (en) 2015-12-23
AU2004224242A1 (en) 2004-10-07
PE20050311A1 (en) 2005-06-06

Similar Documents

Publication Publication Date Title
NO20054876L (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
NO20090321L (en) Use of substituted 2-aminotyethralines for the manufacture of a drug for the prevention, relief and / or treatment of various types of pain
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
WO2007007919A3 (en) Heterocyclic janus kinase 3 inhibitors
NO20074084L (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicaments and medicaments containing them
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
WO2006064033A3 (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
MX2007003157A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, their use as a medicament, and a medicament containing them.
NO20081315L (en) Benzokinazoline derivatives and their use in the treatment of bone disorders
WO2004045618A3 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
SE0301010D0 (en) Novel compounds
NO20082124L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
NO20081434L (en) 5- (Phenylisoxazolylethoxy) triazol-3-yl substituted pyridine compositions for the treatment of neurological, psychiatric or pain disorders
MX2009004908A (en) Chemical compounds.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
NO20054418L (en) Substituted benzoylureidopyridylpiperidine and pyrrolidinecarboxylic acid derivatives, their preparation and use
EA200701868A1 (en) AMINOBUTANE ACID DERIVATIVES, INHIBITING CPT